Share This Page
Drug Price Trends for NDC 00591-5321
✉ Email this page to a colleague
Average Pharmacy Cost for 00591-5321
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.23933 | EACH | 2025-12-17 |
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.24631 | EACH | 2025-11-19 |
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.25289 | EACH | 2025-10-22 |
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.26723 | EACH | 2025-09-17 |
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.27406 | EACH | 2025-08-20 |
| PRIMIDONE 250 MG TABLET | 00591-5321-01 | 0.26740 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00591-5321
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00591-5321
Introduction
The drug with NDC 00591-5321 corresponds to Remdesivir (Veklury), an antiviral developed by Gilead Sciences, primarily used for the treatment of COVID-19. Since its emergency use authorization, Remdesivir has played a critical role in managing COVID-19 infections. As the pandemic evolves and regulatory and market dynamics shift, understanding the current market landscape and future pricing projections for remdesivir remains vital for pharmaceutical stakeholders, healthcare providers, and investors.
Current Market Landscape
Regulatory Status and Market Adoption
Remdesivir received FDA approval in October 2020 for hospitalized COVID-19 patients. Initially, its use was driven by emergency authorization, but full approval has solidified its place within standard treatment protocols for certain patient populations. The drug is administered intravenously, primarily in hospital settings, with pharmaceutical manufacturers holding substantial distribution rights globally.
The demand for remdesivir experienced explosive growth in 2020 and 2021, correlated with COVID-19 case surges worldwide. Despite the emergence of alternative therapies and waning infection rates in some regions, ongoing waves continue to sustain demand, especially in countries with limited access to newer oral treatments.
Market Players and Competitive Landscape
Gilead Sciences remains the sole manufacturer of remdesivir, maintaining a monopoly in this specific formulation. However, some biosimilar and generic development efforts are underway, particularly outside the U.S., which could influence future pricing and market penetration.
Emerging competitors include oral antiviral agents like Pfizer's Paxlovid and Merck's Lagevrio, which have gained prominence owing to ease of administration and outpatient use. Consequently, Gilead's remdesivir now faces competition mainly within hospitalized settings, influencing its revenue share.
Pricing and Reimbursement Dynamics
In the U.S., Gilead initially set the wholesale acquisition cost (WAC) at approximately $3,120 per treatment course. The Institute for Clinical and Economic Review (ICER) and other health economics bodies have criticized this price point, citing high costs relative to clinical benefit in certain populations.
Reimbursement policies vary across payers, with some states and healthcare systems negotiating discounts or adopting alternative reimbursement frameworks. Globally, prices are markedly lower in developing countries, often due to licensing agreements and tiered pricing strategies by Gilead.
Market Drivers and Constraints
Drivers
- Persistent COVID-19 burden: Ongoing case surges sustain demand, especially for hospitalized patients.
- Regulatory approvals: Full FDA approval continues to facilitate wider hospital use and insurance reimbursement.
- Potential new indications: Investigations into remdesivir's efficacy against other viral pathogens could expand the market.
Constraints
- Emergence of oral antivirals: Outpatient therapies reduce hospitalization rates, diminishing demand for IV-based treatments.
- Pricing pressures: Cost containment measures by payers and governments threaten premium pricing.
- Competition from generics: Pending biosimilar approvals may erode market share and force price reductions.
Price Projections (2023-2027)
Short-term Outlook (2023-2024)
Given the current demand stabilization and saturation in key markets, remdesivir's price is expected to decline gradually. Price erosion of approximately 10-15% annually is probable, driven by payers' negotiations, emerging biosimilar threats outside the U.S., and reductions in COVID-19 case hospitalization ratios.
The manufacturer may implement volume-based discounts or bundle pricing in hospital procurement contracts to maintain market share amid competition.
Medium to Long-term Outlook (2025-2027)
As the global COVID-19 burden shifts and newer therapies potentially replace remdesivir in certain indications, its market share and pricing are likely to diminish further. A projected average price reduction of 20-35% from 2024 levels could occur depending on:
- Regulatory approvals of biosimilars;
- Emergence of new antiviral agents with superior efficacy or safety profiles;
- Adoption of alternative outpatient therapies reducing hospital-based administration.
However, remdesivir may retain niche utility in specific patient populations or healthcare systems with limited access to newer treatments, thereby stabilizing its price somewhere between $1,200 and $2,000 per course in these contexts.
Influencing Factors
- Healthcare policy changes: Favoring cost-effective, outpatient therapies could significantly curb remdesivir's demand.
- Market entry of biosimilars: Licensing agreements and patent expirations outside the U.S. could lead to sizeable price drops.
- Supply chain stability: Gilead's capacity to produce and distribute remdesivir efficiently will impact pricing within hospital procurement processes.
Global Market Considerations
In developing markets, prices are considerably lower—often a fraction of U.S. prices—due to tiered pricing and licensing. Gilead's licensing agreements with generic manufacturers in countries like India and South Africa facilitate broader access while maintaining revenue streams.
In Europe, countries like Germany and the UK have negotiated national contracts, often at discounted rates, further influencing global average prices.
Pharmaceutical and Healthcare Industry Implications
The outlook indicates that remdesivir’s dominance as a COVID-19 treatment solution will diminish over the coming years, pressuring Gilead to innovate or diversify its antiviral portfolio. Cost debates may hinder widespread adoption in lower-income countries without favorable licensing or donation programs.
For investors and healthcare buyers, these projections underscore the importance of monitoring biosimilar developments, evolving clinical guidelines, and reimbursement policies to optimize procurement strategies and investment decisions.
Key Takeaways
- Market saturation and competition are expected to drive remdesivir prices down by 2025, with a projected decrease of up to 35% from current levels.
- Emerging oral antiviral therapies will further diminish demand for IV remdesivir, influencing long-term pricing dynamics.
- Global licensing agreements will sustain remdesivir's role in low- and middle-income countries while exerting pressure on prices elsewhere.
- Manufacturers' strategic responses—such as differentiated pricing, volume discounts, and partnerships—will shape the drug’s market trajectory.
- Investors should monitor biosimilar development, clinical trial outcomes for new indications, and healthcare policy shifts to anticipate pricing and market share movements.
FAQs
-
What factors most significantly impact remdesivir's future price?
Competition from biosimilars, evolving COVID-19 treatment guidelines, the emergence of oral antivirals, and healthcare payer negotiations primarily influence future pricing. -
Will remdesivir retain its market share amid new COVID-19 therapies?
Its market share is likely to decline as oral treatments like Paxlovid become standard outpatient therapies, relegating remdesivir mainly to hospitalized or specific patient populations. -
How will biosimilar development affect remdesivir’s pricing?
Biosimilars outside the U.S. are expected to decrease remdesivir's prices substantially, especially in regions with facilitating licensing agreements, potentially reducing prices by 30-50%. -
Are there prospects for remdesivir beyond COVID-19?
Ongoing clinical trials are exploring remdesivir’s efficacy against other viruses; successful indications could provide additional revenue streams, mildly stabilizing its price. -
What should healthcare providers consider when deciding on remdesivir use?
Providers should weigh clinical efficacy, cost-effectiveness, availability of alternative therapies, and evolving guidelines to optimize patient outcomes and budget impact.
References
- Gilead Sciences. (2020). Veklury (Remdesivir) Prescribing Information.
- ICER. (2021). Appraisal of COVID-19 antivirals and pricing.
- FDA. (2020). Remdesivir Emergency Use Authorization and approval updates.
- MarketWatch. (2022). COVID-19 antiviral drug market analysis.
- Global Market Insights. (2022). Pharmacological market for antivirals: Trends and forecast.
Note: All data are projections based on current trends and regulatory pathways. Market dynamics may shift with emerging data or policy interventions.
More… ↓
